GLP-1 Side EffectsEvidence & Dosage

Top studies on GLP-1 Side Effects

Ranked by influential-citation count and publication year.

1. 01

   Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.

   CNS drugs·2005200 influential citations

   Increasing numbers of reports concerning diabetes, ketoacidosis, hyperglycaemia and lipid dysregulation in patients treated with second-generation (or atypical) antipsychotics have raised concerns about a possible association between these…

2. 02

   Public Interest in the Off-Label Use of Glucagon-like Peptide 1 Agonists (Ozempic) for Cosmetic Weight Loss: A Google Trends Analysis.

   Aesthetic surgery journal·2023193 influential citations

   Glucagon-like peptide 1 (GLP-1) agonists are a drug class used for the treatment of diabetes that have recently gained FDA approval for medical management of obesity. The off-label use of Ozempic (Novo Nordisk, Bagsværd, Denmark), the…

3. 03

   Cardiovascular biology of the incretin system.

   Endocrine reviews·2012136 influential citations

   Glucagon-like peptide-1 (GLP-1) is an incretin hormone that enhances glucose-stimulated insulin secretion and exerts direct and indirect actions on the cardiovascular system. GLP-1 and its related incretin hormone, glucose-dependent…

4. 04

   Enhancing incretin action for the treatment of type 2 diabetes.

   Diabetes care·2003106 influential citations

   <h4>Objective</h4>To examine the mechanisms of action, therapeutic potential, and challenges inherent in the use of incretin peptides and dipeptidyl peptidase-IV (DPP-IV) inhibitors for the treatment of type 2 diabetes.<h4>Research design…

5. 05

   The Efficacy of GLP-1 Analogues on Appetite Parameters, Gastric Emptying, Food Preference and Taste Among Adults with Obesity: Systematic Review of Randomized Controlled Trials.

   Diabetes, metabolic syndrome and obesity : targets and therapy·2023·n=44599 influential citations

   <h4>Background</h4>Obesity is an epidemiological issue that negatively affects public health and has led to a high global burden on the healthcare system. Several approaches to control and overcome the obesity crisis have been established.…

6. 06

   Protective properties of GLP-1 and associated peptide hormones in neurodegenerative disorders.

   British journal of pharmacology·202294 influential citations

   Type 2 diabetes mellitus and the associated desensitisation of insulin signalling has been identified as a risk factor for progressive neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease and others. Glucagon‐like…

7. 07

   Role of Glucagon-Like Peptide-1 Receptor Agonists in Achieving Weight Loss and Improving Cardiovascular Outcomes in People With Overweight and Obesity.

   Journal of the American Heart Association·202381 influential citations

   Obesity remains a major public health problem, affecting almost half of adults in the United States. Increased risk of cardiovascular disease (CVD) and CVD mortality are major obesity‐related complications, and management guidelines now…

8. 08

   Incretins, insulin secretion and Type 2 diabetes mellitus.

   Diabetologia·200479 influential citations

   When glucose is taken orally, insulin secretion is stimulated much more than it is when glucose is infused intravenously so as to result in similar glucose concentrations. This effect, which is called the incretin effect and is estimated…

9. 09

   Glucagon-Like Peptide 1 Receptor Agonists in Patients With Inflammatory Arthritis or Psoriasis: A Scoping Review.

   Journal of clinical rheumatology : practical reports on rheumatic &amp; musculoskeletal diseases·202475 influential citations

   <h4>Abstract</h4>Obesity is a proinflammatory state associated with increased disease severity in various types of inflammatory arthritis. Weight loss is associated with improved disease activity in certain forms of inflammatory arthritis…

10. 10

    The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications.

    Endocrine reviews·200774 influential citations

    The hyperglycemic activity of pancreatic extracts was encountered some 80 yr ago during efforts to optimize methods for the purification of insulin. The hyperglycemic substance was named "glucagon," and it was subsequently determined that…